Microwave ablation combined with anti-PD-1 therapy enhances systemic antitumor immunity in a multitumor murine model of Hepa1-6

References

• Chu KF, Dupuy DE. Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat Rev Cancer. 2014;14(3):199–208.
   PubMed Web of Science ®Google Scholar
• Crocetti L, Scalise P, Bozzi E, et al. Microwave ablation of very-early- and early-stage HCC: efficacy evaluation by correlation with histology after liver transplantation. Cancers. 2021;13(14):3420.
   PubMed Web of Science ®Google Scholar
• Bréhier G, Besnier L, Delagnes A, et al. Imaging after percutaneous thermal and non-thermal ablation of hepatic tumour: normal appearances, progression and complications. Br J Radiol. 2021;94(1123):20201327.
   PubMed Web of Science ®Google Scholar
• Yin X-Y, Xie X-Y, Lu M-D, et al. Percutaneous thermal ablation of medium and large hepatocellular carcinoma: long-term outcome and prognostic factors. Cancer. 2009;115(9):1914–1923.
   PubMed Web of Science ®Google Scholar
• Takaki H, Imai N, Thomas CT, et al. Changes in peripheral blood T-cell balance after percutaneous tumor ablation. Minim Invasive Ther Allied Technol. 2017;26(6):331–337.
   PubMed Web of Science ®Google Scholar
• Leuchte K, Staib E, Thelen M, et al. Microwave ablation enhances tumor-specific immune response in patients with hepatocellular carcinoma. Cancer Immunol Immunother. 2021;70(4):893–907.
   PubMed Web of Science ®Google Scholar
• Qian L, Shen Y, Xie J, et al. Immunomodulatory effects of ablation therapy on tumors: potentials for combination with immunotherapy. Biochim Biophys Acta Rev Cancer. 2020;1874(1):188385.
   PubMed Web of Science ®Google Scholar
• Shao C, Yang M, Pan Y, et al. Case report: Abscopal effect of microwave ablation in a patient with advanced squamous NSCLC and resistance to immunotherapy. Front Immunol. 2021;12:696749.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–2454.
   PubMed Web of Science ®Google Scholar
• Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–571.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122–133.
   PubMed Web of Science ®Google Scholar
• Dong HD, Zhu GF, Tamada K, et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999;5(12):1365–1369.
   PubMed Web of Science ®Google Scholar
• Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793–800.
   PubMed Web of Science ®Google Scholar
• Thomas Y, Joong-Won P, Finn Richard S, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. The Lancet Oncol. 2021;23(1):77–90.
   Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–1905.
   PubMed Web of Science ®Google Scholar
• Abd El Aziz MA, Facciorusso A, Nayfeh T, et al. Immune checkpoint inhibitors for unresectable hepatocellular carcinoma. Vaccines. 2020;8(4):616.
   PubMed Web of Science ®Google Scholar
• Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369(2):134–144.
   PubMed Web of Science ®Google Scholar
• Shi L, Chen L, Wu C, et al. PD-1 blockade boosts radiofrequency ablation-elicited adaptive immune responses against tumor. Clin Cancer Res. 2016;22(5):1173–1184.
   PubMed Web of Science ®Google Scholar
• Zhao J, Wen X, Tian L, et al. Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer. Nat Commun. 2019;10(1):899.
   PubMed Web of Science ®Google Scholar
• Schwartz Lawrence H, Saskia L, de Vries E, et al. RECIST 1.1-Update and clarification: from the RECIST committee. Eur J Cancer. 2016;62:132–137.
   PubMed Web of Science ®Google Scholar
• Dong L-Q, Peng L-H, Ma L-J, et al. Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma. J Hepatol. 2020;72(5):896–908.
   PubMed Web of Science ®Google Scholar
• Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20(19):5064–5074.
   PubMed Web of Science ®Google Scholar
• Zhou G, Sprengers D, Boor PPC, et al. Antibodies against immune checkpoint molecules restore functions of tumor-infiltrating T cells in hepatocellular carcinomas. Gastroenterology. 2017;153(4):1107–1119.e10.
   PubMed Web of Science ®Google Scholar
• Okazaki T, Chikuma S, Iwai Y, et al. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol. 2013;14(12):1212–1218.
   PubMed Web of Science ®Google Scholar
• Alvarez M, Simonetta F, Baker J, et al. Indirect impact of PD-1/PD-L1 blockade on a murine model of NK cell exhaustion. Front Immunol. 2020;11:7.
   PubMed Web of Science ®Google Scholar
• Verma V, Shrimali RK, Ahmad S, et al. PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1 + CD38hi cells and anti-PD-1 resistance . Nat Immunol. 2019;20(9):1231–1243.
   PubMed Web of Science ®Google Scholar
• Chen J, Jiang CC, Jin L, et al. Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Ann Oncol. 2016;27(3):409–416.
   PubMed Web of Science ®Google Scholar
• Ruiz de Galarreta M, Bresnahan E, Molina-Sánchez P, et al. β-Catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma. Cancer Discov. 2019;9(8):1124–1141.
   PubMed Web of Science ®Google Scholar
• Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33(17):1974–1982.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264.
   PubMed Web of Science ®Google Scholar
• Dumolard L, Ghelfi J, Roth G, et al. Percutaneous ablation-induced immunomodulation in hepatocellular carcinoma. IJMS. 2020;21(12):4398.
   Web of Science ®Google Scholar
• Velez E, Goldberg SN, Kumar G, et al. Hepatic thermal ablation: effect of device and heating parameters on local tissue reactions and distant tumor growth. Radiology. 2016;281(3):782–792.
   PubMed Web of Science ®Google Scholar
• Tranberg K-G. Local destruction of tumors and systemic immune effects. Front Oncol. 2021;11:708810.
   PubMed Web of Science ®Google Scholar
• Zhou W, Yu M, Pan H, et al. Microwave ablation induces Th1-type immune response with activation of ICOS pathway in early-stage breast cancer. J Immunother Cancer. 2021;9(4):e002343.
   PubMed Web of Science ®Google Scholar
• Fuchs EJ, Matzinger P. Is cancer dangerous to the immune system? Semin Immunol. 1996;8(5):271–280.
   PubMedGoogle Scholar
• Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat Med. 1999;5(11):1249–1255.
   PubMed Web of Science ®Google Scholar
• Mole RH. Whole body irradiation: Radiology or medicine? Br J Radiol. 1953;26(305):234–241.
   Google Scholar
• Li L, Wang W, Pan H, et al. Microwave ablation combined with OK-432 induces Th1-type response and specific antitumor immunity in a murine model of breast cancer. J Transl Med. 2017;15(1):23.
   PubMed Web of Science ®Google Scholar
• Facciorusso A, Abd El Aziz MA, Tartaglia N, et al. Microwave ablation versus radiofrequency ablation for treatment of hepatocellular carcinoma: a meta-analysis of randomized controlled trials. Cancers. 2020;12(12):3796.
   PubMed Web of Science ®Google Scholar
• Slovak R, Ludwig JM, Gettinger SN, et al. Immuno-thermal ablations – boosting the anticancer immune response. J Immunother Cancer. 2017;5(1):78.
   PubMed Web of Science ®Google Scholar
• Gao Q, Qiu SJ, Fan J, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol. 2007;25(18):2586–2593.
   PubMed Web of Science ®Google Scholar
• Cai XY, Gao Q, Qiu SJ, et al. Dendritic cell infiltration and prognosis of human hepatocellular carcinoma. J Cancer Res Clin Oncol. 2006;132(5):293–301.
   PubMed Web of Science ®Google Scholar
• Ruckert M, Deloch L, Frey B, et al. Combinations of radiotherapy with vaccination and immune checkpoint inhibition differently affect primary and abscopal tumor growth and the tumor microenvironment. Cancers. 2021;13(4):714.
   PubMed Web of Science ®Google Scholar